Company profile
GLAUKOS Corp
NYSE:GKOSMedical/Dental Instruments
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MITOMYCIN | approved | — | 4 | approved |
| RIBOFLAVIN 5'-PHOSPHATE | approved | — | 0 | — |
| TRAVOPROST | approved | — | 19 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05966493 | phase2 | recruiting | 2023-08-17 | 2025-12-01 | Glaukos Corporation | A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED |
| NCT03868124 | phase3 | completed | 2018-09-17 | 2022-06-10 | Glaukos Corporation | Clinical Study Comparing Two Models of a Travoprost Intraocular Implant |
| NCT00674661 | phase3 | completed | 2007-12-01 | 2011-11-01 | Glaukos Corporation | Corneal Collagen Cross-Linking for Ectasia (CXL) |
| NCT00647699 | phase3 | completed | 2007-12-01 | 2011-04-01 | Glaukos Corporation | Corneal Collagen Cross-linking for Progressive Keratoconus |
| NCT07629557 | phase4 | recruiting | 2026-05-11 | 2027-09-01 | Glaukos Corporation | Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 022572 | NDA | GLAUKOS CORP | ||||
Loading… | ||||||
| NDA 203324 | NDA | GLAUKOS CORP | ||||
Loading… | ||||||
| NDA 218010 | NDA | GLAUKOS CORP | ||||
Loading… | ||||||
| NDA 219910 | NDA | GLAUKOS CORP | ||||
Loading… | ||||||